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OBJECTIVE — Patients with type 2 diabetes are known to have an increased risk for fracture
comparedwithnon–type2diabeticcontrolsubjects,despitehavinghigherbonemineraldensity
(BMD). We previously showed that serum pentosidine, one of the advanced glycation end
products (AGEs), was associated with prevalent vertebral fractures (VFs) in those with type 2
diabetes. The involvement of the endogenous secretory receptor for AGEs (esRAGE) in VFs in
those with type 2 diabetes, however, is still unknown.
RESEARCH DESIGN AND METHODS — We compared parameters including es-
RAGE, pentosidine, and BMD in Japanese type 2 diabetic patients (137 men 50 years old and
140 postmenopausal women) with and without VFs.
RESULTS — The esRAGE-to-pentosidine ratio in type 2 diabetic patients with VFs was sig-
niﬁcantlylowerthaninthosewithoutVFs(men:7.12.8vs.9.46.2,P0.013,respectively;
women: 4.7  2.7 vs. 8.2  5.4, P  0.001, respectively). Multivariate logistic regression
analysis adjusted for age, BMI, A1C, serum creatinine, duration of diabetes, therapeutic agents,
diabetescomplications,osteoporoticriskfactors,andlumbarBMDidentiﬁedtheserumesRAGE
level and esRAGE-to-pentosidine ratio as factors associated with the presence of VFs, indepen-
dent of BMD in men (odds ratio [OR] 0.46 [95% CI 0.25–0.84], P  0.012; and OR 0.34
[0.15–0.76],P0.009,respectively)andinwomen(OR0.32[0.16–0.67],P0.002;andOR
0.14 [0.04–0.43], P  0.001, respectively).
CONCLUSIONS — These results show that serum esRAGE level and esRAGE-to-
pentosidine ratio are more useful than BMD for assessing the risk of VFs in type 2 diabetic
patients.
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T
he association between diabetes and
osteoporosis has been investigated
in many studies because these two
disorders affect a large proportion of the
elderly population. Recent meta-analyses
of accumulating studies have shown that
patients with type 2 diabetes have an in-
creased risk for hip fracture compared
with non–type 2 diabetic control sub-
jects, despite their higher bone mineral
density(BMD)(1,2).Wehavealsoshown
that patients with type 2 diabetes have an
increasedriskforvertebralfractures(VFs)
and that BMD at any site fails to assess the
risk of VF (3). Because bone strength re-
ﬂects integration of bone density and
bone quality (4), these ﬁndings suggest
that bone quality may be more important
than bone density in deﬁning bone
strength in type 2 diabetic patients.
Bone quality is known to be deter-
mined by bone architecture, turnover, ac-
cumulation of microdamage, miner-
alization, and properties of bone matrix
proteins such as collagen (4). In diabetic
patients, advanced glycation end prod-
ucts (AGEs) are generated by sequential
nonenzymatic glycosylation of protein
amino groups (5). Pentosidine is one of
the well-known AGEs, and its bone con-
tentinspontaneousdiabeticratshasbeen
shown to increase concurrently with the
onset of diabetes, resulting in impaired
mechanicalpropertiesofthebonedespite
normal BMD (6). We have shown clini-
cally that the serum pentosidine level is
associated with the presence of VFs in
postmenopausal diabetic women inde-
pendent of BMD (7). These ﬁndings sug-
gest that AGEs, including pentosidine,
may act as causative factors for poor bone
quality in type 2 diabetic patients.
The receptor for AGEs (RAGE) be-
longstotheimmunoglobulinsuperfamily
of cell surface receptors and is capable of
interacting with multiple ligands, includ-
ing AGEs (8). When transgenic mice
overexpressing human RAGE in vascular
cellswerecrossbredwithatransgenicline
that develops insulin-dependent diabetes
shortlyafterbirth,amoreprogressivehis-
tological change of diabetic nephropathy
wasobservedcomparedwithcontrols(9),
conﬁrming that RAGE is associated with
the development of diabetes complica-
tions. Endogenous secretory RAGE (es-
RAGE), a splice variant of one of the
naturally occurring secretory forms, is
known to carry all the extracellular do-
mains but lacks the transmembrane and
cytoplasmic domains (10). Secreted es-
RAGEintheextracellularspaceisthought
toactasadecoyreceptorthatbindsAGEs
and results in reducing the activity of in-
tercellular signal pathways via RAGE
(10). Indeed, administration of a geneti-
cally engineered murine-soluble RAGE
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atherosclerosisinadose-dependentman-
ner in streptozotocin-induced apoE-null
diabetic mice (11). Recently, RAGE-
knockout mice have been shown to in-
crease BMD and biomechanical bone
strength by decreasing osteoclast forma-
tion as well as serum levels of interleu-
kin-6andpyridinoline(12).Wehavealso
shown that the combination of high glu-
cose with AGEs inhibits osteoblastic min-
eralization through glucose-induced
increases in the expression of RAGE in
vitro (13). These experimental ﬁndings
suggest that enhanced RAGE activity may
also be clinically linked to reduced bone
strength in diabetic patients. Given the
neutralizing nature of esRAGE, it is pos-
sible that the ratio of serum esRAGE-to-
AGE levels could be linked to clinical
bone problems, such as fractures, more
prominently than either parameter alone.
To examine this issue, we compared
serum levels of esRAGE and pentosidine
as well as the esRAGE-to-pentosidine ra-
tio between type 2 diabetic patients with
and without VFs and evaluated the use-
fulness of these markers for assessing the
risk of VFs in the population.
RESEARCH DESIGN AND
METHODS— We consecutively en-
rolled 277 Japanese patients with type 2
diabetes (137 men [age range 50–82
years] and 140 postmenopausal women
[agerange46–87years])whounderwent
BMD measurements at the outpatient
clinic of Shimane University Hospital.
The patients were referred to our hospital
from community clinics for the treatment
of diabetes. We excluded patients who
had higher-than-normal range of serum
creatinine (normal range for women,
0.44–0.83 mg/dl; men, 0.56–1.23
mg/dl) or 300 mg albumin/g urine cre-
atinine for urinary albumin excretion be-
cause serum esRAGE levels are known to
beinﬂuencedbydecreasedrenalfunction
(14). We also excluded patients with an
abnormality of calcium metabolism such
as primary hyperparathyroidism or a his-
tory of falls or trafﬁc accidents to elimi-
nate the possibility of injury-associated
fractures. We deﬁned the onset of type 2
diabetes as the ﬁrst time when glucosuria
or hyperglycemia was noticed. None of
the patients were taking any drugs or
hormones that affected bone metabolism,
including sex steroids, warfarin, and
bisphosphonates. Baseline characteristics
of the subjects are shown in Table 1. Se-
rum esRAGE levels in men (0.294 
0.102ng/ml)andwomen(0.2570.161
ng/ml) were equivalent to those previ-
ously reported in subjects with metabolic
syndrome (0.253  0.111 ng/ml) (15)
and lower than those in normal control
subjects (0.436  0.121 ng/ml) (16). Se-
rum pentosidine levels in men (0.0413 
0.0194 g/ml) and women (0.0400 
0.0159 g/ml) were higher than those
previously reported in normal control
subjects (0.0261  0.0007 g/ml) (17).
Therewere48men(35%)and61women
(44%) with diabetic retinopathy, whereas
83 men (61%) and 93 women (66%) had
diabetic neuropathy. There were 95 men
(69%) and 6 women (4%) who smoked
20 cigarettes/day and 86 (63%) men
and 12 (9%) women with habitual alco-
hol drinking. This study was cross-
sectional and was approved by the ethics
review board of our institution, in com-
pliance with the Declaration of Helsinki.
All subjects agreed to participate in the
study and provided written informed
consent.
Biochemical measurements
Fasting blood was obtained, and fasting
plasma glucose (FPG), A1C, and serum
creatinine were measured by automated
techniques at the central laboratory of
our hospital. Serum bone-speciﬁc alka-
line phosphatase (BAP) and urinary N-
telopeptide (uNTX) were commercially
measured using enzyme-linked immu-
nosorbent assay (ELISA).
Serum concentrations of human
esRAGE were measured using an esRAGE
Table 1—Background data of men and postmenopausal women with type 2 diabetes
Men Women
n 137 140
VFs 52 (37.9) 41 (29.2)
VFs grade 2 or more 19 (13.9) 16 (11.4)
2 VFs 24 (17.5) 15 (10.7)
Age (years) 65.0  7.9 66.9  10.1
BMI (kg/m
2) 23.3  3.3 24.5  4.5
L-BMD (g/cm
2) 1.047  0.198 0.883  0.201
t score 0.02  1.65 1.18  1.80
Z score 0.53  1.14 0.65  1.38
FN-BMD (g/cm
2) 0.765  0.128 0.646  0.130
t score 0.78  0.95 1.29  1.19
Z score 0.31  1.10 0.51  1.23
R-BMD (g/cm
2) 0.691  0.062 0.529  0.088
t score 1.66  1.34 2.57  1.71
Z score 0.51  1.25 0.52  1.56
Serum creatinine (mg/dl) 0.75  0.15 0.60  0.15
Urinary albumin excretion
(mg alb/g urine Cr) 39.7  54.4 30.4  41.6
Fasting plasma glucose
(mg/dl)
167  62 168  59
A1C (%) 8.9  2.4 8.7  2.1
Duration of diabetes (years) 11.8  9.0 12.5  9.8
Pentosidine (g/ml) 0.0413  0.0194 0.0400  0.0159
esRAGE (ng/ml) 0.294  0.102 0.257  0.161
esRAGE-to-pentosidine ratio 8.5  5.3 7.2  5.1
BAP (units/l) 26.0  7.6 31.6  12.9
uNTX (nmol BCE/mmol Cr) 31.6  15.5 52.6  34.2
Use of insulin secretagogue 50 (36) 51 (36)
Use of metformin 28 (20) 38 (27)
Use of pioglitazone 18 (13) 14 (10)
Use of insulin 25 (18) 38 (27)
Diabetic retinopathy 48 (35) 61 (44)
Diabetic neuropathy 83 (61) 93 (66)
Smoking 95 (69) 6 (4)
Alcohol 83 (61) 12 (9)
The data are expressed as n, n (%), or means  SD. alb, albumin; BCE, bone collagen equivalents; Cr,
creatinine.
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Takaoka, Japan) as reported previously
(10,14).Theinterassaycoefﬁcientofvari-
ation (CV) for repeated measurements
ranged from 2.5 to 5.1%. Serum pentosi-
dine levels were detected using a compet-
itive ELISA kit (FSK pentosidine ELISA
kit; Fushimi Pharmaceutical, Kagawa, Ja-
pan) as described previously (7,18). The
inter- and intra-assay CVs of absorbance
were 6.6 and 8.0%, respectively. This
ELISAwashighlycorrelatedwiththecon-
ventional high-performance liquid chro-
matography method (r  0.9356) (18).
Assessment of fractures
In all subjects VFs were identiﬁed on lat-
eralX-rayﬁlmsofthethoracicandlumbar
spine according to the semiquantitative
method (19) by two investigators who
were blinded to the other’s readings. VFs
were classiﬁed as follows: mild (grade 1),
a reduction of 20–25%; moderate (grade
2), 25–40%; severe (grade 3), 40%. If
judgment of VFs was not in agreement,
the ﬁlm was independently reassessed. If
the reevaluated ﬁndings were still different,
we regarded the case as a milder grade.
Densitometry
BMD values of the lumbar spine (L), the
femoral neck (FN), and one-third the ra-
dius (R) were measured by dual-energy
X-ray absorptiometry using the QDR-
4500 system (Hologic, Waltham, MA).
Values were expressed relative to the SD
of age- and sex-matched normal Japanese
mean values of BMD provided by the
manufacturer (Z score). The coefﬁcients
of variation of measurement of the L-,
FN-, and R-BMD were 1.0, 1.0, and
1.0%, respectively.
Statistical analysis
All data are expressed as the means  SD
for each index. An unpaired t test was
used to compare parameters between
subjects with and without VFs. Compar-
isons of categorical variables were made
using a 
2 test. Statistical analyses were
performed using the computer program
StatView for Windows, version 5.0 (SAS
Institute, Cary, NC).
RESULTS— Simple regression analy-
sis revealed that serum esRAGE level in
diabetic men was signiﬁcantly and posi-
tively correlated with creatinine (r 
0.377; P  0.001) and signiﬁcantly and
negatively correlated with t score of R-
BMD (r  0.186; P  0.029). There
were no signiﬁcant correlations between
serum esRAGE levels and age, BMI, other
BMD values, A1C, duration of diabetes,
serum pentosidine level, or bone meta-
bolic markers in either sex (Table 2).
We compared biochemical parame-
ters, including serum esRAGE level and
esRAGE-to-pentosidine ratio, between
type 2 diabetic patients with and without
VFs for each sex (Table 3). Diabetic men
with VFs were signiﬁcantly older (P 
0.001) and shorter in height (P  0.001),
and they had a signiﬁcantly lower
esRAGE-to-pentosidine ratio (P  0.013)
than those without VFs. Diabetic women
with VFs were signiﬁcantly older (P 
0.001) and shorter in height (P  0.021),
and they had a signiﬁcantly higher serum
pentosidine level (P  0.006) and signif-
icantlylowervaluesfortheR-BMDtscore
(P  0.047), serum esRAGE (P  0.007),
and esRAGE-to-pentosidine ratio (P 
0.001) than those without VFs
(Table 4). There were no signiﬁcant dif-
ferences in other BMD values, bone met-
abolic markers, or demographic
confounders such as therapeutic agents,
diabetes complications, smoking status,
or alcohol consumption between those
with and without VFs for either sex.
Todeterminetheassociationbetween
the presence of VFs and serum esRAGE,
pentosidine, and esRAGE/pentosidine ra-
tio, logistic analyses were performed
(Table4).Whennoadjustmentwasmade
(model 1), esRAGE-to-pentosidine ratio
in men and serum esRAGE, pentosidine,
and esRAGE-to-pentosidine ratio in
women were signiﬁcantly associated with
VFs (men: esRAGE-to-pentosidine OR
per SD increase 0.53 [95% CI 0.31–
0.88], P  0.015; and women: esRAGE
OR 0.53 [0.33–0.85], P  0.009; pento-
sidine OR 1.65 [1.13–2.41], P  0.010;
esRAGE-to-pentosidine OR 0.34 [0.19–
0.62], P  0.001). In contrast, no associ-
ations between VFs and BMD at any site
were found in either sex. esRAGE level in
men became signiﬁcantly associated with
VFs after adjustments for age, BMI, A1C,
and creatinine level (model 2). These ob-
servations remained signiﬁcant when
multivariate logistic regression analysis
was performed after the addition of ther-
apeutic agents, the presence of diabetes
complications, and risk factors for os-
teoporosis (e.g., smoking and habitual
alcohol drinking) (model 3). However,
esRAGE, pentosidine, or esRAGE-to-
pentosidine ratio was not associated
with severe VFs, including grade 2/3 or
multiple ones (data not shown).
CONCLUSIONS — This is the ﬁrst
clinicalstudytoshowthatserumesRAGE
level is signiﬁcantly and negatively asso-
ciated with the presence of prevalent VFs
in patients with type 2 diabetes. This as-
sociation was independent of BMD, bone
Table 2—Simple regression analysis between esRAGE level and various parameters
Men Women
rPr P
Age (years) 0.164 0.053 0.003 0.976
BMI (kg/m
2) 0.086 0.323 0.046 0.590
L-BMD (g/cm
2) 0.023 0.791 0.044 0.615
t score 0.016 0.849 0.040 0.647
Z score 0.015 0.864 0.042 0.627
FN-BMD (g/cm
2) 0.147 0.087 0.085 0.325
t score 0.136 0.113 0.078 0.369
Z score 0.064 0.459 0.068 0.466
R-BMD (g/cm
2) 0.126 0.143 0.077 0.383
t score 0.186 0.029* 0.069 0.435
Z score 0.129 0.134 0.086 0.324
Serum creatinine (mg/dl) 0.377 0.001† 0.048 0.571
Urinary albumin excretion
(mg alb/g urine Cr) 0.039 0.654 0.104 0.257
Fasting plasma glucose (mg/dl) 0.106 0.219 0.109 0.199
A1C (%) 0.077 0.371 0.119 0.162
Duration of diabetes (years) 0.086 0.319 0.093 0.278
Pentosidine (g/ml) 0.102 0.235 0.097 0.255
BAP (units/l) 0.101 0.242 0.033 0.699
uNTX (nmol BCE/mmol Cr) 0.026 0.766 0.077 0.371
*P  0.05; †P  0.01. alb, albumin; BCE, bone collagen equivalents; Cr, creatinine.
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diabetes complications, and risk factors
for osteoporosis. esRAGE is known to
bind various ligands, including AGEs, in
the extracellular space and to inhibit the
connection between cell surface RAGE
and ligands (10). Thus, an insufﬁcient
amount of esRAGE to counteract AGEs
could intensify the binding of AGEs to
RAGEandexertharmfuleffectsonorgans
via RAGE-transmitted signals in diabetic
patients. We found that esRAGE was neg-
atively associated with VFs, whereas pen-
tosidine showed a positive association.
esRAGE-to-pentosidine ratio was thought
to be more suitable to assess the risk of
VFs than serum esRAGE level alone be-
cause of its more signiﬁcant P values.
These ﬁndings support the concept that
esRAGE could be beneﬁcial to bones in
those with type 2 diabetes by neutralizing
theharmfuleffectsofpentosidineorother
AGEs rather than by direct activity.
We found that esRAGE was more
signiﬁcantly associated with VFs than
pentosidine in diabetic patients. The as-
sociation between esRAGE and VFs was
signiﬁcantinbothsexesafteradjustments
for multivariate, whereas the association
between pentosidine and VFs was only
signiﬁcant in women. Thus, esRAGE
seems to be more useful than pentosidine
toassesstheriskofVFsirrespectiveofsex
in type 2 diabetes. Several studies have
shown that not only pentosidine but also
other AGEs are harmful to bone. It has
beendocumentedthatRAGEisexpressed
in human bone-derived cells (20) and
that AGE-BSA inhibits the synthesis of
typeIcollagenandosteocalcininprimary
human osteoblasts and the secretion of
parathyroid hormones from human para-
thyroid cells (21). We have also shown
that combination of high glucose with ei-
ther AGE2 or AGE3 inhibits osteocalcin
expression and mineralization through
glucose-induced increases in RAGE ex-
pression in cultured osteoblasts (13).
Thus, various kinds of AGEs seem to im-
pair bone matrix production and miner-
alizationofosteoblasts,whichmayleadto
thebonefragilityseenindiabeticpatients.
Furthermore, esRAGE is known to inter-
act with nonglycated proteins such as
Table 3—Comparison of various parameters between type 2 diabetic patients with and without VFs
Men Women
VFs VFs
No Yes P No Yes P
n 85 52 99 41
Age (years) 62.2  8.0 68.0  6.8 0.001* 64.5  9.5 73.0  3.7 0.001*
Body height (cm) 165.8  6.3 162.1  5.9 0.001* 151.0  5.6 148.6  5.3 0.021†
Body weight (kg) 63.8  10.8 62.0  9.5 0.337 55.4  10.0 55.5  12.3 0.956
BMI (kg/m
2) 23.1  3.5 23.5  3.2 0.514 24.3  3.9 25.2  5.6 0.276
L-BMD (g/cm
2) 1.072  0.217 1.006  0.155 0.056 0.892  0.197 0.853  0.207 0.306
t score 0.19  1.81 0.35  1.30 0.062 1.10  1.78 1.43  1.86 0.345
Z score 0.64  1.28 0.35  0.86 0.142 0.62  1.38 0.65  1.40 0.935
FN-BMD (g/cm
2) 0.772  0.127 0.754  0.101 0.383 0.657  0.138 0.616  0.104 0.097
t score 0.73  1.04 0.85  0.80 0.473 1.19  1.24 1.56  0.96 0.095
Z score 0.28  1.21 0.40  0.90 0.690 0.52  1.25 0.48  1.22 0.846
R-BMD (g/cm
2) 0.697  0.062 0.682  0.063 0.180 0.537  0.092 0.507  0.074 0.067
t score 1.52  1.36 1.88  1.28 0.123 2.39  1.78 3.04  1.45 0.047†
Z score 0.48  1.30 0.57  1.19 0.682 0.50  1.60 0.58  1.50 0.794
Serum creatinine (mg/dl) 0.75  0.16 0.77  0.14 0.396 0.59  0.14 0.64  0.15 0.063
Urinary albumin excretion
(mg alb/g urine Cr) 34.3  46.7 48.0  64.2 0.161 29.4  41.2 33.1  40.0 0.647
Fasting plasma glucose
(mg/dl)
172  68 158  49 0.214 166  57 173  64 0.550
A1C (%) 9.1  2.5 8.5  2.0 0.144 8.8  2.1 8.5  2.1 0.557
Duration of diabetes (years) 12.0  9.0 11.5  9.1 0.757 11.1  9.0 16.0  10.6 0.007*
Pentosidine (g/ml) 0.0388  0.0162 0.0453  0.0233 0.059 0.0377  0.0145 0.0458  0.0181 0.006*
esRAGE (ng/ml) 0.303  0.112 0.280  0.083 0.205 0.282  0.173 0.202  0.109 0.007*
esRAGE-to-pentosidine ratio 9.4  6.2 7.1  2.8 0.013† 8.2  5.5 4.7  2.7 0.001*
BAP (U/l) 26.3  7.7 25.6  7.5 0.635 31.4  13.1 31.9  12.8 0.860
uNTX (nmol BCE/mmol Cr) 32.5  17.6 30.3  11.3 0.428 50.3  29.8 56.1  41.3 0.360
Use of insulin secretagogue 27 (32) 23 (44) 0.197 34 (34) 17 (41) 0.573
Use of metformin 17 (20) 11 (21) 0.999 28 (28) 10 (24) 0.766
Use of pioglitazone 12 (14) 6 (12) 0.842 8 (8) 6 (15) 0.423
Use of insulin 17 (20) 8 (15) 0.630 27 (27) 11 (27) 0.999
Diabetic retinopathy 30 (35) 18 (35) 0.999 43 (43) 18 (44) 0.718
Diabetic neuropathy 50 (59) 33 (63) 0.915 64 (64) 39 (95) 0.627
Smoking 62 (73) 33 (63) 0.412 4 (4) 2 (5) 0.999
Alcohol 49 (58) 34 (65) 0.579 10 (10) 2 (5) 0.490
Data are expressed as n, n (%), or means  SD. Unpaired t test: *P  0.01; †P  0.05. Comparisons of categorical variables were made using 
2 test. alb, albumin;
BCE, bone collagen euivalents; Cr, creatinine.
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calgranulins proteins and nuclear high-
mobility group protein box-1 (HMGB1),
which are released by cellular stress
through RAGE (22). Given that esRAGE
has extensive neutralizing effects against
various AGEs that are harmful to bone as
well as pentosidine, it seems reasonable
that esRAGE was more highly associated
withthepresenceofVFsthanpentosidine
in type 2 diabetic patients in this study.
Thisstudyhassomelimitations.First,
itwasnotpopulation-based,andthesam-
ple size was not large enough to make
deﬁnitive conclusions. Second, the pa-
tients enrolled in this study might have
had relatively severe cases of type 2 dia-
betes and might not be representative of
standardJapanesediabeticpatients,given
thatthediabeticconditionsofthepatients
who attended Shimane University Hospi-
tal, a tertiary care center, were considered
to be more serious than those of other
diabetic patients. Third, we did not ex-
clude patients with confounders known
to affect bone strength to avoid a consid-
erable reduction in the study population.
Diabetic complications such as diabetic
retinopathy, longer diabetes duration,
and a history of insulin treatment are
known to be associated with non-VFs in
diabetic patients (23). A recent meta-
analysis showed that long-term use of
thiazolidinedioneswasassociatedwithan
increased risk of fractures and reduced L-
and FN-BMD in female type 2 diabetic
patients (24). Multiple logistic regression
analysis in this study, however, revealed
that both serum esRAGE levels and the
esRAGE-to-pentosidine ratio were associ-
ated with the presence of VFs indepen-
dent of diabetes complications, duration
of diabetes, or therapeutic agents includ-
ing insulin and pioglitazone, suggesting
that none of these factors affected our ob-
servations. Finally, BMI of our patients
was 23.3 in men and 24.5 in women,
showing that they were less obese by
Western standards. It is well known that
low BMI increases risk for all kind of frac-
tures (25). Although the signiﬁcant re-
sults were still obtained after adjustment
for BMI in the present study, our ﬁndings
need to be conﬁrmed in other ethnic
groups.
In conclusion, we found that serum
esRAGE level as well as esRAGE-to-
pentosidine ratio were signiﬁcantly and
inversely associated with the presence of
prevalent VFs in type 2 diabetic patients.
These associations were independent of
BMD and diabetes-related confounders
and were stronger than serum pentosi-
dine level alone. These ﬁndings suggest
that the AGE-RAGE system as a whole
may affect bone quality, which is not de-
termined by BMD. The present study as
well as our previous studies (3) suggest
that BMD may not be sensitive enough to
assesstheriskofVFs,giventhatBMDwas
notassociatedwiththepresenceofVFsin
type 2 diabetic patients. Serum esRAGE
level and esRAGE-to-pentosidine ratio
seem to be useful surrogate markers,
which could compensate for the ineffec-
tiveness of BMD in evaluating the risk of
VFs in type 2 diabetic patients. However,
our study was cross-sectional, and we did
not investigate non-VFs in the subjects.
Longitudinal studies on both VFs and
non-VFs are needed to prove the impor-
tance of the AGE-RAGE system in assess-
ing the fracture risk of type 2 diabetic
patients.
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